Analysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Atara Biotherapeutics (ATRA)


There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ascendis Pharma (ASND) and Atara Biotherapeutics (ATRA) with bullish sentiments.

Ascendis Pharma (ASND)

In a report released today, Liana Moussatos from Wedbush maintained a Buy rating on Ascendis Pharma, with a price target of $81. The company’s shares opened today at $73.72, close to its 52-week high of $76.99.

According to TipRanks.com, Moussatos ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -11.7% and a 33.6% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics Inc, Allena Pharmaceuticals Inc, and Global Blood Therapeutics.

Currently, the analyst consensus on Ascendis Pharma is a Strong Buy with an average price target of $92, representing a 24.8% upside. In a report issued on January 23, Cantor Fitzgerald also initiated coverage with a Buy rating on the stock with a $102 price target.

See today’s analyst top recommended stocks >>

Atara Biotherapeutics (ATRA)

Mizuho Securities analyst Salim Syed maintained a Buy rating on Atara Biotherapeutics today and set a price target of $62. The company’s shares opened today at $35.93.

According to TipRanks.com, Syed is a 3-star analyst with an average return of 3.2% and a 55.8% success rate. Syed covers the Healthcare sector, focusing on stocks such as Unity Biotechnology Inc, Wave Life Sciences, and Gilead Sciences.

Atara Biotherapeutics has an analyst consensus of Strong Buy, with a price target consensus of $53.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts